应对副作用:乳腺癌妇女每日日记研究,与辅助内分泌疗法生活
W Bierbauer1,2, U Scholz1,2, U Güth3,4
1Applied Social and Health Psychology, Department of Psychology, University of Zurich, Zurich, Switzerland.
Psycho-oncology
|October 25, 2024
概括
接受乳腺癌辅助内分泌疗法 (AET) 的女性在使用面向问题和意义的应对策略来应对副作用时,体验到更好的福祉. 避免和支持应对策略与减少幸福感有关.
科学领域:
- 在瘤学瘤学.
- 心理学 心理学 心理学
- 内分泌学 在内分泌学.
背景情况:
- 辅助内分泌疗法 (AET) 是激素受体阳性乳腺癌的标准治疗方法,常常处方时间长达10年.
- AET与显著的副作用有关,这些副作用可能会对患者的生活质量和情绪健康产生负面影响.
- 患者采用的应对策略可能在适应与药物相关的副作用方面发挥关键作用.
研究的目的:
- 研究应对策略与接受AET的女性心理健康之间的关联.
- 识别不同的应对因素及其与日常幸福感的关系.
- 探索不同的应对机制如何影响适应AET副作用.
主要方法:
- 使用了一种密集的纵向研究设计.
- 参与者 (n=215) 完成了评估应对策略 (简要COPE) 和心理健康 (PHQ-4) 的日常调查.
- 多层次因素分析确定了四个应对因素:以问题为中心,以支持为中心,以意义为中心和以避免为中心. 多层次建模分析了日常应对和副作用作为福祉的预测因素.
主要成果:
- 妇女每天平均报告3.7次副作用,更高的频率和负担与健康状况下降有关.
- 越来越多地使用以问题为中心和以意义为中心的应对策略与心理健康有积极的关联.
- 相反,对以支持为重点和以避免为重点的应对策略的更多依赖与幸福感的下降有关.
结论:
- 应对努力对接受乳腺癌AET的妇女的日常幸福感有显著的影响.
- 以问题和意义为重点的应对策略是适应性的,而以支持和避免为重点的策略可能是有害的.
- 心理社会干预,如认知行为疗法,可以为患者提供有效的应对机制,以管理AET副作用.
相关概念视频
Menopause
143
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
143
Disorders of the Female Reproductive System
332
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
332
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
175
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
175


